CHIMERIX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8999 USD | +1.00% |
|
+1.75% | -6.50% |
| 21/03 | Chimerix Appoints Marc D. Kozin to Board of Directors | CI |
| 29/02 | Transcript : Chimerix, Inc., Q4 2023 Earnings Call, Feb 29, 2024 |
| Sales 2024 * | 8M 667M | Sales 2025 * | 2.14M 179M | Capitalization | 80.66M 6.73B |
|---|---|---|---|---|---|
| Net income 2024 * | -76M -6.34B | Net income 2025 * | -92M -7.67B | EV / Sales 2024 * | 10.1 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 37.6 x |
| P/E ratio 2024 * |
-1.06
x | P/E ratio 2025 * |
-0.94
x | Employees | 72 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Chimerix, Inc.
More recommendations
More press releases
More news
| 1 day | +1.00% | ||
| 1 week | +1.75% | ||
| Current month | -15.10% | ||
| 1 month | -10.90% | ||
| 3 months | -3.19% | ||
| 6 months | -7.82% | ||
| Current year | -6.50% |
1 week
0.88
0.94
1 month
0.881.07
Current year
0.881.30
1 year
0.881.57
3 years
0.889.29
5 years
0.8811.57
10 years
0.8858.04
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Andriole
CEO | Chief Executive Officer | 51 | 08/19/08 |
| Director of Finance/CFO | - | 01/11/01 | |
Michael Sherman
CHM | Chairman | 58 | 08/19/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Clarence Machado
BRD | Director/Board Member | 60 | 20/14/20 |
Fred Middleton
BRD | Director/Board Member | 74 | 28/18/28 |
Martha Demski
BRD | Director/Board Member | 71 | 01/05/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +6.26% | - | |
| 0.00% | 147 M€ | +4.88% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.8999 | +1.00% | 228,222 |
| 25/24/25 | 0.891 | -1.66% | 242,708 |
| 24/24/24 | 0.906 | -2.09% | 88,247 |
| 23/24/23 | 0.9253 | +1.25% | 182,129 |
| 22/24/22 | 0.9139 | +3.34% | 233,440 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
Calendar
01/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.8999
USD
Average target price
7
USD
Spread / Average Target
+677.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.50% | 80.66M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CMRX Stock
